Transactions by persons discharging managerial responsibilities and persons closely associated with them Mediclinic International plc (Incorporated in England and Wales) Company Number: 08338604 LSE Share Code: MDC JSE Share Code: MEI NSX Share Code: MEP ISIN: GB00B8HX8Z88 LEI: 2138002S5BSBIZTD5I60 (“Mediclinic”, the “Company” or the “Group”) 10 August 2018 NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM On 8 August 2018, Mr Jurgens Myburgh, Chief Financial Officer of Mediclinic International plc, acquired 20,000 shares in the Company at ZAR 86.82 per share. Accordingly, Mr Myburgh now owns a total of 80,000 shares in Mediclinic International plc. The following notification is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation. 1. Details of PDMR / persons closely associated with them (“PCA”) a) Name Mr Petrus Jurgens Myburgh 2. Reason for the notification a) Position / status Chief Financial Officer of the Company b) Initial notification / Initial Notification amendment 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Mediclinic International plc b) LEI 2138002S5BSBIZTD5I60 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Ordinary Shares financial instrument Identification Code GB00B8HX8Z88 b) Nature of the Purchase of shares transaction c) Price(s) and volume(s) Price(s) Volume(s) ZAR 86.82 per share 20 000 d) Aggregated information Aggregated volume 20 000 Price ZAR 86.82 e) Date of the 8 August 2018; 14:21 UTC transaction f) Place of the Johannesburg Stock Exchange transaction About Mediclinic International plc Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE- listed and UK-based private healthcare group. Mediclinic comprises 74 hospitals and 30 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 48 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 24 clinics with more than 700 inpatient beds in the United Arab Emirates. Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia. For further information, please contact: Company Secretary, Link Company Matters Limited Jayne Meacham / Caroline Emmet +44 (0)20 7954 9569 Investor Relations, Mediclinic International plc James Arnold, Head of Investor Relations ir@mediclinic.com +44 (0)20 3786 8181 Media queries FTI Consulting Brett Pollard/Debbie Scott – UK +44 (0)20 3727 1000 Sherryn Schooling – South Africa +27 (0)21 487 9000 Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom Website: www.mediclinic.com Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited) NSX sponsor: Simonis Storm Securities (Pty) Ltd Date: 10/08/2018 03:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.